Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain

Clinical and Translational Oncology

Volumn 12, Issue 2, 2010, Pages 75-80

  Rosell, Rafael ^a,b   Morán, Teresa ^a   Carcereny, Enric ^a   Quiroga, Vanessa ^a   Molina, Miguel Ángel ^b   Costa, Carlota ^b   Benlloch, Susana ^b   Tarón, Miquel ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

EGFR mutations; Non small cell lung cancer; Serum DNA; T790M

Indexed keywords

CISPLATIN; CYCLOPAMINE; DASATINIB; DOUBLE STRANDED DNA; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHOTRANSFERASE;

ASIAN; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER STEM CELL; CANCER SURVIVAL; CAUCASIAN; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DNA MODIFICATION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; EXON; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HOMOLOGOUS RECOMBINATION; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PHARMACOGENETICS; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; REVIEW; SURVIVAL TIME; TREATMENT RESPONSE; BIOLOGICAL MODEL; CHEMISTRY; DRUG RESISTANCE; GENETIC DATABASE; GENETICS; LUNG TUMOR; MUTATION; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; SPAIN; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DATABASES, GENETIC; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; MUTATION; PHOSPHOTRANSFERASES; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPAIN;

EID: 77951631364     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/S12094-010-0473-0     Document Type: Review

References (47)

1. Gazdar AF (2009) Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 361:1018-1020
2. Sordella R, Bell DW, Haber DA, Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305:1163-1167
3. Jackman DM, Miller VA, Cioffredi LA et al (2009) Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 15:5267-5273
4. Sequist LV, Martins RG, Spigel D et al (2008) First-line gefitinib in patients with advanced nonsmall- cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26:2442-2449
5. Riely GJ, Pao W, Pham D et al (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12:839-844
6. Gandhi J, Zhang J, Xie Y et al (2009) Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS ONE 4:e4576
7. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957
8. Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958-967
9. Seike M, Goto A, Okano T et al (2009) MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A 106:12085-12090
10. Meng F, Henson R, Wehbe-Janek H et al (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133:647-658
11. Kuang Y, Rogers A, Yeap BY et al (2009) Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 15:2630-2636
12. Rosell R, Viteri S, Molina MA et al (2009) Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall- cell lung cancer. Curr Opin Oncol (in press)
13. Nguyen KS, Kobayashi S, Costa DB (2009) Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-smallcell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 10:281-289
14. Zhou W, Ercan D, Chen L et al (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462:1070-1074
15. Maheswaran S, Sequist LV, Nagrath S et al (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359:366-377
16. Inukai M, Toyooka S, Ito S et al (2006) Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 66:7854-7858
17. Dierks C, Beigi R, Guo GR et al (2008) Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14:238-249
18. Zhao C, Chen A, Jamieson CH et al (2009) Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458:776-779
19. Kobayashi S, Shimamura T, Monti S et al (2006) Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res 66:11389-11398
20. Chen JK, Taipale J, Cooper MK, Beachy PA (2002) Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 16:2743-2748
21. Viswanathan SR, Daley GQ, Gregory RI (2008) Selective blockade of microRNA processing by Lin28. Science 320:97-100
22. West JA, Viswanathan SR, Yabuuchi A et al (2009) A role for Lin28 in primordial germ-cell development and germ-cell malignancy. Nature 460:909-913
23. Viswanathan SR, Powers JT, Einhorn W et al (2009) Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 41:843-848
24. Mendell JT (2009) Tumors line up for a letdown. Nat Genet 41:768-769
25. Johnson CD, Esquela-Kerscher A, Stefani G et al (2007) The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67:7713-7722
26. Kumar MS, Erkeland SJ, Pester RE et al (2008) Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A 105:3903-3908
27. Cortez MA, Calin GA (2009) MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Exp Opin Biol Ther 9:703-711
28. Meyer B, Krisponeit D, Junghanss C et al (2007) Quantitative expression analysis in peripheral blood of patients with chronic myeloid leukaemia: correlation between HMGA2 expression and white blood cell count. Leuk Lymphoma 48:2008-2013
29. Langelotz C, Schmid P, Jakob C et al (2003) Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer. Br J Cancer 88:1406-1410
30. Shell S, Park SM, Radjabi AR et al (2007) Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A 104:11400-11405
31. Wu X, Piper-Hunter MG, Crawford M et al (2009) MicroRNAs in the pathogenesis of Lung Cancer. J Thorac Oncol 4:1028-1034
32. Yanaihara N, Caplen N, Bowman E et al (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9:189-198
33. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105-111
34. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall- cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
35. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500
36. Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311
37. Taron M, Ichinose Y, Rosell R et al (2005) Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11:5878-5885
38. Smouse JH, Cibas ES, Janne PA et al (2009) EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer Cytopathol 117:67-72
39. Molina-Vila MA, Bertran-Alamillo J, Reguart N et al (2008) A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol 3:1224-1235
40. Morita S, Okamoto I, Kobayashi K et al (2009) Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 15:4493-4498
41. Miyazawa H, Tanaka T, Nagai Y et al (2008) Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation. Cancer Sci 99:595-600
42. Yu J, Kane S, Wu J et al (2009) Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 15:3023-3028
43. Motoi N, Szoke J, Riely GJ et al (2008) Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 32:810-827
44. De Oliveira Duarte Achcar R, Nikiforova MN, Yousem SA (2009) Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. Am J Clin Pathol 131:694-700
45. Gow CH, Chang YL, Hsu YC et al (2009) Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-smallcell lung cancer. Ann Oncol 20:696-702
46. Bai H, Mao L, Wang HS et al (2009) Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 27:2653-2659
47. Yung TK, Chan KC, Mok TS et al (2009) Single molecule detection of epidermal growth factor receptor mutations in plasma by micro fluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 15:2076-2084